Bluejay Diagnostics, Inc.

NasdaqCM BJDX

Bluejay Diagnostics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -592.61%

Bluejay Diagnostics, Inc. Net Income Margin is -592.61% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Bluejay Diagnostics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -3,443.68%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: BJDX

Bluejay Diagnostics, Inc.

CEO	Mr. Indranil Dey
IPO Date	Nov. 10, 2021
Location	United States
Headquarters	360 Massachusetts Avenue
Employees	10
Sector	Health Care
Industries Biotechnology Medical Instruments

Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Key trends

Past 5 years